by Peter Ciszewski | Sep 25, 2017
New data are set to change the paradigm for the first-line treatment of advanced renal cell carcinoma (RCC), after a phase 3 trial showed significantly improved overall survival (OS) with immunotherapy in comparison to standard care with sunitinib (Sutent,...
by Peter Ciszewski | Sep 25, 2017
Cancer patients continue to understand what is involved in a clinical trial, even when they have participated in them. In a survey of 1090 adult cancer patients, more than half did not understand the concepts of clinical equipoise or randomization. In the survey, 63%...
by Peter Ciszewski | Sep 25, 2017
Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses Livatag, a nanoparticle formulation of doxorubicin (Transdrug technology) developed for the treatment of primary liver cancer.
by Peter Ciszewski | Sep 25, 2017
A minimally invasive laparoscopic procedure to resect esophageal cancer dramatically reduces postoperative morbidity in comparison with open surgery, and also appears to improve survival. The new results from MIRO, a randomized, controlled trial in which the two...
by Peter Ciszewski | Sep 25, 2017
Targeted therapy and immunotherapy in oncology took center stage once again at Europe’s leading oncology meeting, as new data showed that the drugs are effective not only in the palliative setting but also in earlier stages of the disease. The European Society...
